eligibility_summary
Adults with completely resected stage II-IIIB (N2) NSCLC, disease-free, received adjuvant platinum chemo, start pembrolizumab <=24 weeks post-surgery, controlled HBV/HCV/HIV allowed. Exclude SCLC/mixed neuroendocrine/sarcomatoid tumors, prior neoadjuvant/radiation/PD-1/PD-L1 therapy, recent systemic therapy/vaccines/investigational use, immunodeficiency/immunosuppression, other active cancers, significant autoimmune, pneumonitis, or active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: 1) Intismeran autogene (V940/mRNA‑4157) – a personalized therapeutic mRNA cancer vaccine (biologic). It delivers lipid nanoparticle–encapsulated mRNA encoding up to dozens of patient-specific tumor neoantigens. Host cells translate these antigens, which are presented on MHC I/II to prime and expand neoantigen‑specific CD8+ and CD4+ T cells, enhancing tumor‑directed immunity. 2) Pembrolizumab (MK‑3475, KEYTRUDA) – an anti‑PD‑1 IgG4 monoclonal antibody checkpoint inhibitor that blocks PD‑1 on T cells, preventing PD‑L1/PD‑L2–mediated inhibition and sustaining T‑cell effector function. Cells/pathways targeted: dendritic cell antigen processing/presentation, MHC I/II pathways, activation and expansion of cytotoxic and helper T cells, PD‑1/PD‑L1 immune checkpoint axis within the adaptive antitumor response.